New Risk • Mar 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$2.43m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Market cap is less than US$10m (US$2.43m market cap). Reported Earnings • Mar 08
First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025) First half 2026 results: US$0.01 loss per share (improved from US$0.42 loss in 1H 2025). Revenue: US$62.8m (down 12% from 1H 2025). Net loss: US$60.2k (loss narrowed 97% from 1H 2025). New Risk • Feb 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 6.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (US$30.9m market cap). Buy Or Sell Opportunity • Jan 15
Now 27% undervalued Over the last 90 days, the stock has risen 47% to US$2.36. The fair value is estimated to be US$3.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%. Annuncio • Dec 30
Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Transaction Features: At the Market Offering Buy Or Sell Opportunity • Nov 20
Now 27% undervalued Over the last 90 days, the stock has risen 236% to US$4.17. The fair value is estimated to be US$5.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%. Annuncio • Nov 13
Ridgetech, Inc., Annual General Meeting, Dec 12, 2025 Ridgetech, Inc., Annual General Meeting, Dec 12, 2025, at 09:00 China Standard Time. Location: 5th floor, building 6, no. 100, 18th street, baiyang sub-district, qiantang district, zhejiang province, p. r. china, 310008., hangzhou China Annuncio • Oct 23
Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million. Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.
Security Name: Ordinary Shares
Security Type: Common Stock Annuncio • Sep 26
Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.
Security Name: Ordinary Shares
Security Type: Common Stock Reported Earnings • Jul 29
Full year 2025 earnings released: US$0.26 loss per share (vs US$2.93 loss in FY 2024) Full year 2025 results: US$0.26 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$120.0m (down 22% from FY 2024). Net loss: US$1.46m (loss narrowed 66% from FY 2024). New Risk • Mar 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$5.80m market cap). Annuncio • Feb 07
China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025 China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025, at 10:00 China Standard Time. Location: located at 4th floor, building 5, renxin yaju, gon, gong shu district, zhejiang, hangzhou city, China New Risk • Jan 30
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.82m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$9.82m market cap). Reported Earnings • Jan 16
First half 2025 earnings released: US$0.42 loss per share (vs US$0.77 loss in 1H 2024) First half 2025 results: US$0.42 loss per share. Revenue: US$71.2m (down 9.4% from 1H 2024). Net loss: US$2.28m (loss widened 146% from 1H 2024). New Risk • Oct 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (295% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.8m market cap). New Risk • Aug 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.72m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$9.72m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Reported Earnings • Aug 01
Full year 2024 earnings released: US$2.93 loss per share (vs US$41.46 loss in FY 2023) Full year 2024 results: US$2.93 loss per share (improved from US$41.46 loss in FY 2023). Revenue: US$154.5m (up 3.8% from FY 2023). Net loss: US$4.23m (loss narrowed 80% from FY 2023). Annuncio • Jun 01
China Jo-Jo Drugstores, Inc. Announces Resignation of Pingfan Wu as Member of the Board of Directors China Jo-Jo Drugstores, Inc. announced that Ms. Pingfan Wu has resigned from her position as a member of the board of directors (the "Board") due to personal reasons, effective on May 31, 2024. The resignation of Ms. Wu did not result from any disagreement with the Company on any matter relating to the Company's business operations, financial reporting or controls, policies or practices. Annuncio • Apr 30
China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million. China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 900,000
Price\Range: $1.7
Transaction Features: Registered Direct Offering New Risk • Apr 01
New major risk - Revenue and earnings growth Revenue has declined by 9.5% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.5% over the past year. Shareholders have been substantially diluted in the past year (65% increase in shares outstanding). Market cap is less than US$10m (US$5.30m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). New Risk • Jan 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$7.47m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Share price has been volatile over the past 3 months (12% average weekly change). Annuncio • Nov 15
China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023 China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023, at 21:00 US Eastern Standard Time. Location: Hai Wai Hai Tongxin Mansion Floor 6, Gong Shu District, Hangzhou City, Zhejiang Province, P. R. China, 310008 Zhejiang China Agenda: To elect six directors to serve until the next Annual Meeting or until their successors are duly elected and qualified;to ratify the appointment of YCM CPA, Inc. as the Company's independent registered public accounting firm for the fiscal year ending March 31,2024; to approve by ordinary resolution the proposed reverse stock split and consolidation of the Company's issued and outstanding ordinary shares;to approve by ordinary resolution the increase of authorized share capital;to approve by special resolution the Amendment of the Memorandum and Articles of Association of the Company to effect the reverse stock split and consolidation of the Company's issued and outstanding ordinary shares, and the increase of authorized share capital;to approve the Third Amended and Restated 2010 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting or any adjournment thereof. New Risk • Jun 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.89m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$9.89m market cap). Annuncio • Jun 18
China Jo-Jo Drugstores Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency On June 16, 2023, China Jo-Jo Drugstores, Inc. announced that on June 15, 2023, the company has received a notification letter from Nasdaq Listing Qualifications Department (‘Nasdaq’) notifying the Company that it is not in compliance with the minimum bid price requirement from May 3, 2023 through June 14, 2023. As set forth in Nasdaq Listing Rules 5550(a)(2) (‘Nasdaq Listing Rule’), it requires that the closing bid price for the Company's ordinary shares listed on Nasdaq be maintained at a minimum of USD 1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency. The notification has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until December 12, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's ordinary shares will continue to trade on the Nasdaq Capital Market. If at any time during this 180 day period, or before December 12, 2023, the closing bid price of the Company's ordinary shares is at least USD 1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement. In the event the Company does not regain compliance by December 12, 2023, the Company may be eligible for additional time to regain compliance, if the Company provide written notice of its intention to cure the deficiency during the second compliance period and is in compliance with the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market. The company intends to monitor the closing bid price of its ordinary shares between now and December 12, 2023. In the event the Company is not eligible for additional time to regain compliance with the Nasdaq requirements towards the end of the first compliance period, the company's Board of Directors will consider options that may be available to achieve compliance. Reported Earnings • Jun 16
Full year 2023 earnings released: US$2.07 loss per share (vs US$0.92 loss in FY 2022) Full year 2023 results: US$2.07 loss per share (further deteriorated from US$0.92 loss in FY 2022). Revenue: US$148.8m (down 9.5% from FY 2022). Net loss: US$21.1m (loss widened US$17.9m from FY 2022). Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 29
Full year 2022 earnings released: US$0.92 loss per share (vs US$2.39 loss in FY 2021) Full year 2022 results: US$0.92 loss per share (up from US$2.39 loss in FY 2021). Revenue: US$164.4m (up 24% from FY 2021). Net loss: US$3.19m (loss narrowed 61% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Annuncio • Apr 28
China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement China Jo-Jo Drugstores, Inc. announced on April 27, 2022 that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on April 25, 2022, notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement and the matter is closed. On July 26, 2021, the Company was first notified by Nasdaq its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A), and was given its first 180-day extension, or until January 24, 2022 to regain compliance. On January 25, 2022, the Company received a second 180-day extension from Nasdaq or until July 25, 2022 to regain compliance. Effective April 7, 2022, the Company effected a 1-for-12 reverse stock split. The letter dated April 25, 2022 the Company received from Nasdaq noted that as of April 22, 2022, the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the last 11 consecutive business days, from April 7, 2022 through April 22, 2022. Nasdaq stated that accordingly, Jo-Jo Drugstores has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and the matter is closed. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jan 27
China Jo-Jo Drugstores Granted Extension to Meet Nasdaq Minimum Bid Price Requirement China Jo-Jo Drugstores, Inc. announced that on January 25, 2022, the Company received another 180 calendar day extension from Nasdaq's Listing Qualifications Department to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days. The Company now has until July 25, 2022 to regain compliance. If at any time before July 25, 2022, the bid price of the Company's ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed. The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A) on July 26, 2021, and was given until January 24, 2022 to regain compliance. Reported Earnings • Jan 22
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up US$1.73m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Board Change • Nov 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 01
Full year 2021 earnings released: US$0.20 loss per share (vs US$0.18 loss in FY 2020) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: US$133.1m (up 14% from FY 2020). Net loss: US$8.12m (loss widened 40% from FY 2020). Like-for-like sales growth: Down 1.3% vs FY 2020 Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 05
New 90-day low: US$0.98 The company is down 11% from its price of US$1.10 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 10.0% over the same period. Reported Earnings • Feb 14
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.016 profit in 3Q 2020) The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$35.5m (up 6.5% from 3Q 2020). Net loss: US$6.26m (down US$6.79m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 06
New 90-day high: US$1.24 The company is up 16% from its price of US$1.07 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period. Is New 90 Day High Low • Jan 12
New 90-day high: US$1.15 The company is up 22% from its price of US$0.94 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period. Annuncio • Dec 24
China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement China Jo-Jo Drugstores, Inc., on December 23, 2020 announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which concerns minimum bid price listing requirements. As previously disclosed, on October 16, 2020, Nasdaq notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over 30 consecutive business days as required by the Nasdaq Listing Rules. On December 17, 2020, Nasdaq provided confirmation to the Company that for the last 20 consecutive business days, from November 18 to December 14, 2020, the closing bid price of the Company's common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2). Reported Earnings • Nov 18
Second quarter 2021 earnings released: US$0.039 loss per share The company reported a soft second quarter result with increased losses and weaker control over expenses, although revenues were improved. Second quarter 2021 results: Revenue: US$30.8m (up 8.8% from 2Q 2020). Net loss: US$1.49m (loss widened 22% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 31
New 90-day low: US$0.90 The company is down 25% from its price of US$1.20 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 6.0% over the same period. Is New 90 Day High Low • Oct 15
New 90-day low: US$0.91 The company is down 32% from its price of US$1.35 on 17 July 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 10.0% over the same period. 
